Furthermore, since the status of EGFR mutation in patients with advanced lung adenocarcinoma may change during the process of therapy, multiple biopsies may be required and this presents a challenge to both the patients and physicians.[16]. This evidence concerns the gene EGFR and lung adenocarcinoma.